This article only represents the author's own views.
Leading Chinese biopharma companies have been balanced on a knife edge for months as a draft U.S. law threatens to restrict their access to the U.S. drugs market. But their position just became rather less precarious.
Concern about the proposed biosecurity crackdown has slashed the share prices of contract manufacturers and research providers on the U.S. list of targeted companies, including firms in China’s WuXi biotech group. But the threat of a sudden business rupture receded last week after the revised bill, including an extended timeline, passed a key legislative hurdle in the U.S. Congress.
您已閱讀10%（654字），剩余90%（5933字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。